Bulevirtide 2 mg and Brelovitug - 300 mg clinical trials

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

This study compares two new treatments, brelovitug and bulevirtide, for chronic Hepatitis Delta. It aims to see which is more effective for people with this liver condition, helping us find better long-term solutions.